An observational, retrospective, single Centre study assessing baseline demographic and HIV-related characteristics and evaluate effectiveness, tolerability, safety, and specific laboratory parameters in all patients who achieved 6 and 12 months of follow-up
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Therapeutic Use
Most Recent Events
- 16 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the 16th International Congress on Drug Therapy and HIV Infection